Clementia Pharmaceuticals Inc.
CMTA
CMTA was delisted on the 17th of April, 2019.
31 hedge funds and large institutions have $352M invested in Clementia Pharmaceuticals Inc. in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
34% more capital invested
Capital invested by funds: $263M → $352M (+$89.5M)
15% more funds holding
Funds holding: 27 → 31 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$22.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$18.7M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$7.04M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$6.56M |
| 5 |
JP Morgan Chase
New York
|
+$5.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.38M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$871K |
| 3 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$653K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$641K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$126K |
CMTA Hedge Fund Activity: Q4 2018 in Review
31 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Clementia Pharmaceuticals Inc. (CMTA) for Q4 2018, worth a combined $352M — up 34% from $263M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CMTA positions and 5 closed out — a net gain of 4 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $22.3M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $1.38M sold.
- 31 institutional investors held Clementia Pharmaceuticals Inc. (CMTA) as of Q4 2018, up from 27 in Q3 2018.
- Funds reported $352M of Clementia Pharmaceuticals Inc. stock for Q4 2018, up 34% quarter-over-quarter.
- 9 funds opened new Clementia Pharmaceuticals Inc. positions in Q4 2018 and 5 closed out, a net change of +4 holders.
- The largest Clementia Pharmaceuticals Inc. buyer in Q4 2018 was Baker Bros. Advisors, an estimated $22.3M added.
- The largest Clementia Pharmaceuticals Inc. seller in Q4 2018 was Sectoral Asset Management, an estimated $1.38M sold.
Based on aggregated 13F filings for Q4 2018.